The central THαβ immunity associated cytokine: IL-10 has a strong anti-tumor ability toward established cancer models in vivo and toward cancer cells in vitro

Cancer immunotherapy is a promising new approach for cancer treatment. We propose to use a new host immunological pathway: TH{beta} immunity for cancer treatment. TH{beta} immunity is a natural host immunity which can be used IFN-/{beta} and its major effectors are IL-10 and IL-15. Thus, we here used these cytokines for treatment both in a mice breast cancer 4T1 model and in a neuroblastoma NXS2 model. 4T1 cells and NXS2 cells were inoculated subcutaneously to wild type BALB/c female mice and AJ mice, respectively. Both Cytokines and an antibody treatment with variable dosages were given. Our results show that IL-10 and IL-15 treatments have significant effects on not only tumor volume shrinkage and but also on mice survival. However, IFN-{gamma} even worsens the tumor volume and mice survival. Antibodies plus IL-10 is no better than IL-10 alone for cancer immunotherapy. This can be due to GD2 antigen expression on immune cells. Moreover, an anti-GD2 antibody could harm immune cells themselves. We found that IL-10 has direct toxicity on tumor cells in vitro. Our results conclude that using TH{beta} immunity is a good strategy for cancer immunotherapy.